Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$5.03 +3.7%	$5.20	$3.79 ▼ $14.60	$243M	-0.87	1.47 million shs	899,689 shs
DBVT DBV Technologies	$9.21 +6.6%	$9.22	$2.20 ▼ $12.78	$236.65M	-0.63	190,045 shs	21,083 shs
NGNE Neurogene	$16.57 -1.8%	$17.23	$6.88 ▼ $74.49	$240.74M	1.57	249,282 shs	117,117 shs
PYRGF PyroGenesis Canada	$0.33 +0.5%	$0.34	$0.30 ▼ $0.80	$62.22M	0.89	11,041 shs	9,752 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+3.71%	+2.24%	-10.18%	-15.46%	-11.91%
DBVT DBV Technologies	+6.60%	-6.50%	-0.86%	+48.55%	+94.32%
NGNE Neurogene	-1.84%	-9.45%	-3.04%	+14.12%	-48.23%
PYRGF PyroGenesis Canada	+0.45%	-4.28%	-0.21%	-7.42%	-35.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.4761 of 5 stars	3.5	3.0	2.5	0.8	0.6
DBVT DBV Technologies	4.0714 of 5 stars	4.3	5.0	3.2	2.5	0.6
NGNE Neurogene	3.6839 of 5 stars	4.4	3.0	1.6	2.5	1.3
PYRGF PyroGenesis Canada	0.1314 of 5 stars	0.0	2.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	317.50% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	60.15% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	178.62% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PYRGF, DBVT, CADL, and NGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,100.03	N/A	N/A	$1.41 per share	3.57
DBVT DBV Technologies	$4.15M	60.79	N/A	N/A	$1.42 per share	6.49
NGNE Neurogene	$930K	254.07	N/A	N/A	$20.89 per share	0.79
PYRGF PyroGenesis Canada	$9.14M	6.81	N/A	N/A	($0.01) per share	-33.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
PYRGF PyroGenesis Canada	-$21.12M	-$0.02	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest PYRGF, DBVT, CADL, and NGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
DBVT DBV Technologies	N/A	0.72	0.72
NGNE Neurogene	N/A	21.03	21.03
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DBVT DBV Technologies	71.74%
NGNE Neurogene	52.37%
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
DBVT DBV Technologies	1.44%
NGNE Neurogene	11.64%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
PYRGF PyroGenesis Canada	90	186.69 million	96.34 million	No Data

PYRGF, DBVT, CADL, and NGNE Headlines

Recent News About These Companies

PyroGenesis Canada Inc. (NASDAQ:PYRGF) Sees Large Increase in Short Interest

June 17, 2025 | marketbeat.com

PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier

June 12, 2025 | globenewswire.com

PyroGenesis Announces Extension to Term of Warrants

June 9, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Trading Up 1.1% - What's Next?

June 1, 2025 | marketbeat.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

PyroGenesis Closes $2,385,000 First Tranche in Previously Announced Loan

May 12, 2025 | globenewswire.com

PyroGenesis Schedules First Quarter 2025 Financial Results and Business Update Conference Call

May 9, 2025 | globenewswire.com

PyroGenesis Announces Closing of Non-Brokered Private Placement of up to $5,750,000

May 5, 2025 | globenewswire.com

P. Peter Pascali Updates Early Warning Report

April 10, 2025 | globenewswire.com

PyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call Transcript

April 1, 2025 | seekingalpha.com

PyroGenesis Announces Fourth Quarter and Full Year 2024 Results

March 31, 2025 | globenewswire.com

PyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference Call

March 26, 2025 | globenewswire.com

PyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling Project

March 21, 2025 | finanznachrichten.de

PyroGenesis Provides Update on Varennes Carbon Recycling Project

March 21, 2025 | globenewswire.com

HPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica Production

March 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF, DBVT, CADL, and NGNE Company Descriptions

Candel Therapeutics NASDAQ:CADL

$5.03 +0.18 (+3.71%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$5.01 -0.02 (-0.30%)

As of 08:06 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.21 +0.57 (+6.60%)

Closing price 06/26/2025 03:53 PM Eastern

Extended Trading

$9.13 -0.08 (-0.83%)

As of 07:27 AM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Neurogene NASDAQ:NGNE

$16.57 -0.31 (-1.84%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$16.64 +0.07 (+0.39%)

As of 07:51 AM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

PyroGenesis Canada NASDAQ:PYRGF

$0.33 +0.00 (+0.45%)

As of 06/26/2025 03:45 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time